Loading stock data…
ProQR Therapeutics N.V (PRQR)
$2.05-0.02 (-0.97%)
Market ClosedLast close Sep 8
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ProQR Therapeutics N.V. in the Healthcare sector is trading at $2.05 with a market capitalization of $159M. Wall Street consensus targets $8.22 (9 analysts), implying a +301.1% move over the next 12 months. The stock is currently 34% below its 52-week high of $3.10, remaining 14.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +301.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.03M↓ | $4.69M↑ | $2.88M↓ | $3.82M↓ | $4.52M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.65M↓ | -$9.10M↑ | -$11.28M↑ | -$12.25M↓ | -$10.82M |
| Net Income | -$13.38M↓ | -$8.92M↑ | -$11.01M↑ | -$12.18M↓ | -$10.08M |
Peer Comparison
JNJUNHPFE
Fundamentals
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$158.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-120.99%
Volume
Today's trading volume
449,150
Recent News
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Undervalued Penny Stocks To Consider In June 2026
Over the last 7 days, the United States market has dropped 2.5%, but it remains up 23% over the past year with earnings forecasted to grow by 17% annually. For investors looking beyond well-known stocks, penny stocks—often representing smaller or newer companies—can present intriguing opportunities despite their somewhat outdated label. By focusing on those with strong financial health and potential for growth, investors might uncover valuable options in this niche area of the market.
ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%
Today is shaping up negative for ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shareholders, with the analysts delivering a...
Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -40.02% and -2.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.